{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:09:55Z","timestamp":1793088595490,"version":"4.5.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.bone.2020.115390","type":"journal-article","created":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T17:19:10Z","timestamp":1588007950000},"page":"115390","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"special_numbering":"C","title":["Zoledronate"],"prefix":"10.1016","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6021-5458","authenticated-orcid":false,"given":"Ian R.","family":"Reid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan R.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth W.","family":"Lyles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Trechsel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Hosking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis M.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Graham G.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik F.","family":"Eriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2020.115390_bb0005","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1021\/jm020819i","article-title":"Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa)","volume":"45","author":"Widler","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bone.2020.115390_bb0010","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/jbmr.5650090521","article-title":"Preclinical pharmacology of CGP 42,446, a new, potent, heterocyclic bisphosphonate compound","volume":"9","author":"Green","year":"1994","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115390_bb0015","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1600-0773.1997.tb01964.x","article-title":"Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models","volume":"80","author":"Green","year":"1997","journal-title":"Pharmacol. Toxicol."},{"key":"10.1016\/j.bone.2020.115390_bb0020","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1359\/jbmr.1998.13.11.1775","article-title":"Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys","volume":"13","author":"Binkley","year":"1998","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115390_bb0025","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00223-002-2015-4","article-title":"Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats","volume":"72","author":"Hornby","year":"2003","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2020.115390_bb0030","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00198-004-1588-3","article-title":"Loss of vertebral bone and mechanical strength in estrogen-deficient rats is prevented by long-term administration of zoledronic acid","volume":"15","author":"Glatt","year":"2004","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115390_bb0035","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1124\/dmd.108.021071","article-title":"Biodistribution and plasma protein binding of zoledronic acid","volume":"36","author":"Weiss","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bone.2020.115390_bb0040","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0022-3565(24)38786-5","article-title":"Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates","volume":"296","author":"Dunford","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bone.2020.115390_bb0045","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1021\/jm7015733","article-title":"Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase","volume":"51","author":"Dunford","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bone.2020.115390_bb0050","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","article-title":"Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite","volume":"38","author":"Nancollas","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.bone.2020.115390_bb0055","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/jbmr.3138","article-title":"The pharmacological profile of a novel highly potent bisphosphonate, OX14 (1-Fluoro-2-(Imidazo-[1,2-\u03b1]Pyridin-3-yl)-ethyl-bisphosphonate)","volume":"32","author":"Lawson","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115390_bb0060","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","article-title":"Intravenous zoledronic acid in postmenopausal women with low bone mineral density","volume":"346","author":"Reid","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2020.115390_bb0065","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00198-007-0367-3","article-title":"Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis","volume":"18","author":"Devogelaer","year":"2007","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115390_bb0070","doi-asserted-by":"crossref","first-page":"E1130","DOI":"10.1503\/cmaj.161207","article-title":"Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial","volume":"189","author":"Grey","year":"2017","journal-title":"CMAJ"},{"key":"10.1016\/j.bone.2020.115390_bb0075","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-pivotal fracture Trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115390_bb0080","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1210\/jc.2014-1971","article-title":"Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?","volume":"99","author":"Cosman","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2020.115390_bb0085","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/jbmr.2442","article-title":"The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-pivotal fracture trial (PFT)","volume":"30","author":"Black","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115390_bb0090","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00198-003-1460-x","article-title":"The contribution of hip fracture to risk of subsequent fractures: data from two longitudinal studies","volume":"14","author":"Colon-Emeric","year":"2003","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115390_bb0095","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2020.115390_bb0100","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1359\/jbmr.090704","article-title":"Potential mediators of the mortality reduction with Zoledronic acid after hip fracture","volume":"25","author":"Colon-Emeric","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115390_bb0105","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.bone.2018.06.004","article-title":"Fracture incidence and secular trends between 1989 and 2013 in a population based cohort: the Rotterdam study","volume":"114","author":"Trajanoska","year":"2018","journal-title":"Bone"},{"key":"10.1016\/j.bone.2020.115390_bb0110","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1808082","article-title":"Fracture prevention with zoledronate in older women with osteopenia","volume":"379","author":"Reid","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2020.115390_bb0115","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/joim.12901","article-title":"Anti-fracture efficacy of zoledronate in subgroups of osteopenic postmenopausal women: secondary analysis of a randomized controlled trial","volume":"286","author":"Reid","year":"2019","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.bone.2020.115390_bb0120","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/jbmr.3860","article-title":"Effects of Zoledronate on Cancer, cardiac events, and mortality in Osteopenic older women","volume":"35","author":"Reid","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115390_bb0125","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","article-title":"Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials","volume":"386","author":"Coleman","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2020.115390_bb0130","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1161\/01.ATV.0000210016.89991.2a","article-title":"Optical imaging of hydroxyapatite in the calcified vasculature of transgenic animals","volume":"26","author":"Zaheer","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.bone.2020.115390_bb0135","doi-asserted-by":"crossref","first-page":"24266","DOI":"10.1074\/jbc.273.37.24266","article-title":"Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by rho GTPase","volume":"273","author":"Laufs","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2020.115390_bb0140","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/jbmr.3660","article-title":"Amino-bisphosphonates and cardiovascular risk: a new hypothesis involving the effects on Gamma-Delta T cells","volume":"34","author":"Giollo","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115390_bb0145","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.2174\/138161210793563635","article-title":"Bisphosphonates: molecular mechanisms of action and effects on Bone cells, monocytes and macrophages","volume":"16","author":"Roelofs","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bone.2020.115390_bb0150","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1001\/jamainternmed.2019.2779","article-title":"Association between drug treatments for patients with osteoporosis and overall mortality rates: a meta-analysis","volume":"179","author":"Cummings","year":"2019","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.bone.2020.115390_bb0155","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJMoa044241","article-title":"Comparison of a single infusion of zoledronic acid with risedronate for Paget\u2019s disease","volume":"353","author":"Reid","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2020.115390_bb0160","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/jbmr.438","article-title":"A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years","volume":"26","author":"Reid","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115390_bb0165","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1359\/jbmr.061001","article-title":"Long-term control of bone turnover in Paget\u2019s disease with zoledronic acid and risedronate","volume":"22","author":"Hosking","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115390_bb0170","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/jbmr.3029","article-title":"Durability of response to Zoledronate treatment and competing mortality in Paget\u2019s disease of Bone","volume":"32","author":"Cundy","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115390_bb0175","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00223-017-0261-8","article-title":"Long-term Bone Scintigraphy results after intravenous Zoledronate in Paget\u2019s disease of Bone","volume":"101","author":"Reid","year":"2017","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2020.115390_bb0180","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/bonekey.2013.176","article-title":"Re-treatment of relapsed Paget\u2019s disease of bone with zoledronic acid - results from an open-label study","volume":"2","author":"Reid","year":"2013","journal-title":"BoneKEy Rep."},{"key":"10.1016\/j.bone.2020.115390_bb0185","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4103\/ijem.IJEM_327_18","article-title":"Response to zoledronic acid in patients with active Paget\u2019s disease of bone: a retrospective study","volume":"23","author":"Durgia","year":"2019","journal-title":"Indian Journal of Endocrinology and Metabolism"},{"key":"10.1016\/j.bone.2020.115390_bb0190","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00223-013-9812-9","article-title":"Remission over 3 years in patients with Paget disease of bone treated with a single intravenous infusion of 5 mg zoledronic acid","volume":"94","author":"Devogelaer","year":"2014","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2020.115390_bb0195","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00296-010-1648-2","article-title":"Paget\u2019s disease of bone: analysis of 134 cases from an island in southern Brazil: another cluster of Paget\u2019s disease of bone in South America","volume":"32","author":"de Castro","year":"2012","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.bone.2020.115390_bb0200","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s00223-016-0214-7","article-title":"Long-term effects of intravenous Ibandronate in Paget\u2019s disease of Bone","volume":"100","author":"Reid","year":"2017","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2020.115390_bb0205","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.bone.2004.03.023","article-title":"Comparative responses of bone turnover markers to bisphosphonate therapy in Paget\u2019s disease of bone","volume":"35","author":"Reid","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.bone.2020.115390_bb0210","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00223-013-9711-0","article-title":"In vitro and in vivo responses to high and low doses of nitrogen-containing bisphosphonates suggest engagement of different mechanisms for inhibition of osteoclastic bone resorption","volume":"92","author":"Fisher","year":"2013","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2020.115390_bb0215","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(09)60250-6","article-title":"Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"373","author":"Reid","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2020.115390_bb0220","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1002\/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K","article-title":"Risedronate therapy prevents corticosteroid-induced bone loss - a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"42","author":"Cohen","year":"1999","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bone.2020.115390_bb0225","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1359\/jbmr.2000.15.6.1006","article-title":"Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial","volume":"15","author":"Reid","year":"2000","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115390_bb0230","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.bone.2011.10.024","article-title":"Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate","volume":"50","author":"Sambrook","year":"2012","journal-title":"Bone"},{"key":"10.1016\/j.bone.2020.115390_bb0235","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00198-012-2060-4","article-title":"Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice","volume":"24","author":"Thomas","year":"2013","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115390_bb0240","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1093\/rheumatology\/kes410","article-title":"Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids","volume":"52","author":"Devogelaer","year":"2013","journal-title":"Rheumatology"},{"key":"10.1016\/j.bone.2020.115390_bb0245","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1359\/jbmr.070906","article-title":"Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure","volume":"23","author":"Recker","year":"2008","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115390_bb0250","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1172\/JCI119668","article-title":"Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis","volume":"100","author":"Chavassieux","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bone.2020.115390_bb0255","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1002\/jbmr.149","article-title":"Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies","volume":"25","author":"Reid","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115390_bb0260","first-page":"1890","article-title":"Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women","volume":"86","author":"Harris","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2020.115390_bb0265","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1359\/jbmr.1999.14.7.1217","article-title":"Hormone replacement therapy prevents osteoclastic hyperactivity: a histomorphometric study in early postmenopausal women","volume":"14","author":"Eriksen","year":"1999","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115390_bb0270","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.bone.2009.11.004","article-title":"Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: the DIVA study","volume":"46","author":"Recker","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.bone.2020.115390_bb0275","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S8756-3282(02)00869-4","article-title":"Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis","volume":"31","author":"Eriksen","year":"2002","journal-title":"Bone"},{"key":"10.1016\/j.bone.2020.115390_bb0280","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2020.115390_bb0285","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1742-1241.2008.01704.x","article-title":"A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International","volume":"62","author":"Reid","year":"2008","journal-title":"Int. J. Clin. Prac."},{"key":"10.1016\/j.bone.2020.115390_bb0290","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment - the Fracture Intervention Trial long-term extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2020.115390_bb0295","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2020.115390_bb0300","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2020.115390_bb0305","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s00198-004-1602-9","article-title":"Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study","volume":"15","author":"Delmas","year":"2004","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115390_bb0310","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1210\/jc.2011-3060","article-title":"Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis","volume":"97","author":"Murad","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2020.115390_bb0315","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women\u2019s Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2020.115390_bb0320","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1210\/jc.2012-2868","article-title":"Reduction in the risk of clinical fractures after a single dose of zoledronic Acid 5 milligrams","volume":"98","author":"Reid","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2020.115390_bb0325","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00198-011-1563-8","article-title":"Treatment with acetaminophen\/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg","volume":"23","author":"Wark","year":"2012","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115390_bb0330","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1\u201334)] in postmenopausal osteoporosis","volume":"26","author":"Cosman","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115390_bb0335","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2020.115390_bb0340","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1002\/art.24879","article-title":"Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis thirty-six-month results of a randomized, double-blind, controlled trial","volume":"60","author":"Saag","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bone.2020.115390_bb0345","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/AOG.0b013e3181bdce0a","article-title":"Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass a randomized controlled trial","volume":"114","author":"McClung","year":"2009","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.bone.2020.115390_bb0350","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nm1786","article-title":"Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging","volume":"14","author":"Varela","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.bone.2020.115390_bb0355","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1161\/CIRCULATIONAHA.116.022188","article-title":"Clinical trial of the protein farnesylation inhibitors lonafarnib, pravastatin, and zoledronic acid in children with Hutchinson-Gilford progeria syndrome","volume":"134","author":"Gordon","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.bone.2020.115390_bb0360","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/stem.2255","article-title":"Zoledronate attenuates accumulation of DNA damage in mesenchymal stem cells and protects their function","volume":"34","author":"Misra","year":"2016","journal-title":"Stem Cells"},{"key":"10.1016\/j.bone.2020.115390_bb0365","doi-asserted-by":"crossref","first-page":"7829","DOI":"10.1073\/pnas.0601643103","article-title":"The molecular mechanism of nitrogen-containing bisphosphonates as anti osteoporosis drugs","volume":"103","author":"Kavanagh","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bone.2020.115390_bb0370","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00198-015-3234-7","article-title":"The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study","volume":"26","author":"Papapoulos","year":"2015","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115390_bb0375","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/nrendo.2015.71","article-title":"Short-term and long-term effects of osteoporosis therapies","volume":"11","author":"Reid","year":"2015","journal-title":"Nat. Rev. Endocrinol."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220301708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220301708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:47:33Z","timestamp":1757612853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328220301708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":75,"alternative-id":["S8756328220301708"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2020.115390","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Zoledronate","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2020.115390","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115390"}}